Analysts Offer Insights on Healthcare Companies: Disc Medicine (IRON) and Nautilus Biotechnolgy (NAUT)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Disc Medicine (IRON – Research Report) and Nautilus Biotechnolgy (NAUT – Research Report) with bullish sentiments.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Disc Medicine (IRON)
In a report released today, Tara Bancroft from TD Cowen maintained a Buy rating on Disc Medicine. The company’s shares closed last Thursday at $67.91, close to its 52-week high of $68.73.
According to TipRanks.com, Bancroft is a 5-star analyst with an average return of
Currently, the analyst consensus on Disc Medicine is a Strong Buy with an average price target of $106.50, which is a 57.8% upside from current levels. In a report issued on February 11, Wedbush also maintained a Buy rating on the stock with a $110.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Nautilus Biotechnolgy (NAUT)
TD Cowen analyst Daniel Brennan maintained a Buy rating on Nautilus Biotechnolgy today. The company’s shares closed last Thursday at $2.42.
According to TipRanks.com, Brennan is a 5-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Nautilus Biotechnolgy with a $2.50 average price target.
